Drug Resistant Epilepsy, Traumatic Brain Injury Without Open Intracranial Wound
Conditions
Keywords
Genomics, Proteomics, Metabolomics, Drug Resistant Epilepsy, Traumatic Brain Injury
Brief summary
In patients with drug-resistant epilepsy (DRE), there may be changes at the genetic, proteomic, and metabolomic levels when comparing epileptic tissues from DRE to normal tissues in traumatic brain injury (TBI). These changes could help in understanding the pathophysiological mechanisms of epilepsy and in identifying new therapeutic targets.
Detailed description
Genomical studies have identified changes in the expression of certain genes within epileptic tissues. These genes may be involved in pathways related to the balance of neuronal excitability and inhibition, synaptic transmission, and cell apoptosis. Proteomic studies will reveal changes in the abundance and modifications of proteins in epileptic tissues. These could involve proteins related to the control of neuronal excitability and synaptic transmission, such as ion channels, neurotransmitter receptors, and synaptic proteins. Metabolomic researches will reveal changes in metabolites within epileptic tissues. Epilepsy may lead to disruptions in metabolic pathways, affecting key processes such as energy metabolism, amino acid metabolism, and lipid metabolism. Sample Size: There is no minimum or maximum, but is expected to be far less than 10. In summary, patients with drug-resistant epilepsy might have changes in genes, proteomics, and metabolomics within epileptic tissues compared to normal tissue from TBI. Further research into these changes will deepen our understanding of the pathophysiology of epilepsy and guide the need for new treatment strategies.
Interventions
Routine clinical treatment is based on the latest international guidelines for DRE.
Sponsors
Xuanwu Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. 14-60 years old, male or female, Han Chinese; 2. Drug-resistant epilepsy; 3. Required surgical implantation of SEEG electrodes.
Exclusion criteria
1. Progressive encephalopathy or progressive structural damage in the central nervous system; 2. Significant heart, liver, renal insufficiency, and other medical diseases; 3. Severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for SEEG; 4. Significant intellectual disability; 5. A history of alcohol and drug abuse; 6. Any contraindication to MRI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Single cell RNA sequencing | through study completion, an average of one year | Cancerous and paracancerous tissues of patients will be subjected to10x Genomics single-cell RNA sequencing, Bulk RNA-seq and spatial transcriptome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Differentially expressed proteins | through study completion, an average of one year | Discovering differentially expressed proteins (DEPs) and their roles in DRE patients, we will conduct 4D-DIA quantitative proteomics analysis. |
| The concentration of metabolites | through study completion, an average of one year | Metabolites of cancerous and paracancerous tissues in patients will be subjected to LC-MS/MS, GC-MS and Desorption Electrospray Ionization - Imaging Mass Spectrometry. |
Countries
China
Contacts
Primary ContactWenfeng Zhao, MD
Backup ContactXiaolei Liu, MD & PhD
Outcome results
None listed